Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of CT-P41 vs Prolia in Healthy Males
NCT06037395Phase 1Completed
- Sponsor
- Celltrion
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of denosumab in osteoporosis (2 arms), sponsored by Celltrion. Primary endpoints: Area under the concentration-time curve from time zero to infinity at Day 253, Area under the concentration-time curve from time zero to the last quantifiable concentration at Day 253 and 1 more. Started Oct 2021; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06037395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06037395.